Print page |
Email page
| 
Download PDF
« Previous Release | Next Release »
SAN DIEGO, Sept 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will be presenting at the following investment conferences:
-- Senior Vice President and Chief Commercial Officer Scott Byrd will
present on Wednesday, September 16, 2009 at 10:30am Eastern Time (7:30am
Pacific Time) during the BioCentury Newsmakers Conference at the
Millennium Hotel in New York City.
-- President and CEO Ted Schroeder will present on Tuesday, September 22,
2009 at 12:00pm Eastern Time (9:00am Pacific Time) during the UBS Global
Life Science Conference at the Grand Hyatt Hotel in New York City.
Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of each webcast will be available approximately three hours following the live webcasts and will be archived for 30 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.
Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.
Contacts: William R. LaRue
SVP, CFO
Cadence Pharmaceuticals, Inc.
858-436-1400
SOURCE Cadence Pharmaceuticals, Inc.
http://www.cadencepharm.com
Copyright (C) 2009 PR Newswire. All rights reserved